Positron emission tomography with computed tomography imaging (PET/CT) for the radiotherapy planning definition of the biological target volume: PART 2
• FDG-PET has an important and promising role for the definition of RT target volume, including Stereotactic body RT for pancreatic cancer. • Choline PET/CT could be useful for identifying high-risk RT volumes, including nodes, for prostate cancer; while PSMA PET/CT is still under evaluation for the...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Fiorentino, Alba [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2019transfer abstract |
|---|
| Schlagwörter: |
|---|
| Umfang: |
8 |
|---|
| Übergeordnetes Werk: |
Enthalten in: miR-214 in stroma cells and tumor progression - Dettori, D. ELSEVIER, 2016, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:139 ; year:2019 ; pages:117-124 ; extent:8 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.critrevonc.2019.03.008 |
|---|
| Katalog-ID: |
ELV047229942 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV047229942 | ||
| 003 | DE-627 | ||
| 005 | 20230626015226.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 191021s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.critrevonc.2019.03.008 |2 doi | |
| 028 | 5 | 2 | |a GBV00000000000665.pica |
| 035 | |a (DE-627)ELV047229942 | ||
| 035 | |a (ELSEVIER)S1040-8428(19)30060-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 44.52 |2 bkl | ||
| 100 | 1 | |a Fiorentino, Alba |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Positron emission tomography with computed tomography imaging (PET/CT) for the radiotherapy planning definition of the biological target volume: PART 2 |
| 264 | 1 | |c 2019transfer abstract | |
| 300 | |a 8 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a • FDG-PET has an important and promising role for the definition of RT target volume, including Stereotactic body RT for pancreatic cancer. • Choline PET/CT could be useful for identifying high-risk RT volumes, including nodes, for prostate cancer; while PSMA PET/CT is still under evaluation for the RT target definition. • FDG-PET has an important and promising role for the definition of RT target volume, including Stereotactic body RT for pancreatic cancer. • FDG PET-CT is the most sensitive imaging modality for detecting nodes metastases in gynecological cancer and has been shown to impact external-beam radiotherapy planning by modifying the treatment field. • FDG-PET/CT can be used to evaluate features at presentation, therapy response and it could be useful for assessing the oncological outcomes of anal and rectal cancer | ||
| 520 | |a • FDG-PET has an important and promising role for the definition of RT target volume, including Stereotactic body RT for pancreatic cancer. • Choline PET/CT could be useful for identifying high-risk RT volumes, including nodes, for prostate cancer; while PSMA PET/CT is still under evaluation for the RT target definition. • FDG-PET has an important and promising role for the definition of RT target volume, including Stereotactic body RT for pancreatic cancer. • FDG PET-CT is the most sensitive imaging modality for detecting nodes metastases in gynecological cancer and has been shown to impact external-beam radiotherapy planning by modifying the treatment field. • FDG-PET/CT can be used to evaluate features at presentation, therapy response and it could be useful for assessing the oncological outcomes of anal and rectal cancer | ||
| 650 | 7 | |a Target volume |2 Elsevier | |
| 650 | 7 | |a Imaging |2 Elsevier | |
| 650 | 7 | |a PET/CT |2 Elsevier | |
| 650 | 7 | |a Radiotherapy |2 Elsevier | |
| 700 | 1 | |a Laudicella, Riccardo |4 oth | |
| 700 | 1 | |a Ciurlia, Elisa |4 oth | |
| 700 | 1 | |a Annunziata, Salvatore |4 oth | |
| 700 | 1 | |a Lancellotta, Valentina |4 oth | |
| 700 | 1 | |a Mapelli, Paola |4 oth | |
| 700 | 1 | |a Tuscano, Carmelo |4 oth | |
| 700 | 1 | |a Caobelli, Federico |4 oth | |
| 700 | 1 | |a Evangelista, Laura |4 oth | |
| 700 | 1 | |a Marino, Lorenza |4 oth | |
| 700 | 1 | |a Quartuccio, Natale |4 oth | |
| 700 | 1 | |a Fiore, Michele |4 oth | |
| 700 | 1 | |a Borghetti, Paolo |4 oth | |
| 700 | 1 | |a Chiaravalloti, Agostino |4 oth | |
| 700 | 1 | |a Ricci, Maria |4 oth | |
| 700 | 1 | |a Desideri, Isacco |4 oth | |
| 700 | 1 | |a Alongi, Pierpaolo |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier Science |a Dettori, D. ELSEVIER |t miR-214 in stroma cells and tumor progression |d 2016 |g Amsterdam [u.a.] |w (DE-627)ELV019637179 |
| 773 | 1 | 8 | |g volume:139 |g year:2019 |g pages:117-124 |g extent:8 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.critrevonc.2019.03.008 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a GBV_ILN_11 | ||
| 912 | |a GBV_ILN_20 | ||
| 912 | |a GBV_ILN_70 | ||
| 912 | |a GBV_ILN_100 | ||
| 912 | |a GBV_ILN_2006 | ||
| 912 | |a GBV_ILN_2009 | ||
| 912 | |a GBV_ILN_2014 | ||
| 912 | |a GBV_ILN_2015 | ||
| 912 | |a GBV_ILN_2016 | ||
| 912 | |a GBV_ILN_2048 | ||
| 936 | b | k | |a 44.52 |j Therapie |x Medizin |q VZ |
| 951 | |a AR | ||
| 952 | |d 139 |j 2019 |h 117-124 |g 8 | ||
| author_variant |
a f af |
|---|---|
| matchkey_str |
fiorentinoalbalaudicellariccardociurliae:2019----:oirnmsinoorpyihoptdoorpymgnpttoteaiteaylnigeiiin |
| hierarchy_sort_str |
2019transfer abstract |
| bklnumber |
44.52 |
| publishDate |
2019 |
| allfields |
10.1016/j.critrevonc.2019.03.008 doi GBV00000000000665.pica (DE-627)ELV047229942 (ELSEVIER)S1040-8428(19)30060-5 DE-627 ger DE-627 rakwb eng 610 VZ 610 VZ 44.52 bkl Fiorentino, Alba verfasserin aut Positron emission tomography with computed tomography imaging (PET/CT) for the radiotherapy planning definition of the biological target volume: PART 2 2019transfer abstract 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • FDG-PET has an important and promising role for the definition of RT target volume, including Stereotactic body RT for pancreatic cancer. • Choline PET/CT could be useful for identifying high-risk RT volumes, including nodes, for prostate cancer; while PSMA PET/CT is still under evaluation for the RT target definition. • FDG-PET has an important and promising role for the definition of RT target volume, including Stereotactic body RT for pancreatic cancer. • FDG PET-CT is the most sensitive imaging modality for detecting nodes metastases in gynecological cancer and has been shown to impact external-beam radiotherapy planning by modifying the treatment field. • FDG-PET/CT can be used to evaluate features at presentation, therapy response and it could be useful for assessing the oncological outcomes of anal and rectal cancer • FDG-PET has an important and promising role for the definition of RT target volume, including Stereotactic body RT for pancreatic cancer. • Choline PET/CT could be useful for identifying high-risk RT volumes, including nodes, for prostate cancer; while PSMA PET/CT is still under evaluation for the RT target definition. • FDG-PET has an important and promising role for the definition of RT target volume, including Stereotactic body RT for pancreatic cancer. • FDG PET-CT is the most sensitive imaging modality for detecting nodes metastases in gynecological cancer and has been shown to impact external-beam radiotherapy planning by modifying the treatment field. • FDG-PET/CT can be used to evaluate features at presentation, therapy response and it could be useful for assessing the oncological outcomes of anal and rectal cancer Target volume Elsevier Imaging Elsevier PET/CT Elsevier Radiotherapy Elsevier Laudicella, Riccardo oth Ciurlia, Elisa oth Annunziata, Salvatore oth Lancellotta, Valentina oth Mapelli, Paola oth Tuscano, Carmelo oth Caobelli, Federico oth Evangelista, Laura oth Marino, Lorenza oth Quartuccio, Natale oth Fiore, Michele oth Borghetti, Paolo oth Chiaravalloti, Agostino oth Ricci, Maria oth Desideri, Isacco oth Alongi, Pierpaolo oth Enthalten in Elsevier Science Dettori, D. ELSEVIER miR-214 in stroma cells and tumor progression 2016 Amsterdam [u.a.] (DE-627)ELV019637179 volume:139 year:2019 pages:117-124 extent:8 https://doi.org/10.1016/j.critrevonc.2019.03.008 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_11 GBV_ILN_20 GBV_ILN_70 GBV_ILN_100 GBV_ILN_2006 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2016 GBV_ILN_2048 44.52 Therapie Medizin VZ AR 139 2019 117-124 8 |
| spelling |
10.1016/j.critrevonc.2019.03.008 doi GBV00000000000665.pica (DE-627)ELV047229942 (ELSEVIER)S1040-8428(19)30060-5 DE-627 ger DE-627 rakwb eng 610 VZ 610 VZ 44.52 bkl Fiorentino, Alba verfasserin aut Positron emission tomography with computed tomography imaging (PET/CT) for the radiotherapy planning definition of the biological target volume: PART 2 2019transfer abstract 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • FDG-PET has an important and promising role for the definition of RT target volume, including Stereotactic body RT for pancreatic cancer. • Choline PET/CT could be useful for identifying high-risk RT volumes, including nodes, for prostate cancer; while PSMA PET/CT is still under evaluation for the RT target definition. • FDG-PET has an important and promising role for the definition of RT target volume, including Stereotactic body RT for pancreatic cancer. • FDG PET-CT is the most sensitive imaging modality for detecting nodes metastases in gynecological cancer and has been shown to impact external-beam radiotherapy planning by modifying the treatment field. • FDG-PET/CT can be used to evaluate features at presentation, therapy response and it could be useful for assessing the oncological outcomes of anal and rectal cancer • FDG-PET has an important and promising role for the definition of RT target volume, including Stereotactic body RT for pancreatic cancer. • Choline PET/CT could be useful for identifying high-risk RT volumes, including nodes, for prostate cancer; while PSMA PET/CT is still under evaluation for the RT target definition. • FDG-PET has an important and promising role for the definition of RT target volume, including Stereotactic body RT for pancreatic cancer. • FDG PET-CT is the most sensitive imaging modality for detecting nodes metastases in gynecological cancer and has been shown to impact external-beam radiotherapy planning by modifying the treatment field. • FDG-PET/CT can be used to evaluate features at presentation, therapy response and it could be useful for assessing the oncological outcomes of anal and rectal cancer Target volume Elsevier Imaging Elsevier PET/CT Elsevier Radiotherapy Elsevier Laudicella, Riccardo oth Ciurlia, Elisa oth Annunziata, Salvatore oth Lancellotta, Valentina oth Mapelli, Paola oth Tuscano, Carmelo oth Caobelli, Federico oth Evangelista, Laura oth Marino, Lorenza oth Quartuccio, Natale oth Fiore, Michele oth Borghetti, Paolo oth Chiaravalloti, Agostino oth Ricci, Maria oth Desideri, Isacco oth Alongi, Pierpaolo oth Enthalten in Elsevier Science Dettori, D. ELSEVIER miR-214 in stroma cells and tumor progression 2016 Amsterdam [u.a.] (DE-627)ELV019637179 volume:139 year:2019 pages:117-124 extent:8 https://doi.org/10.1016/j.critrevonc.2019.03.008 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_11 GBV_ILN_20 GBV_ILN_70 GBV_ILN_100 GBV_ILN_2006 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2016 GBV_ILN_2048 44.52 Therapie Medizin VZ AR 139 2019 117-124 8 |
| allfields_unstemmed |
10.1016/j.critrevonc.2019.03.008 doi GBV00000000000665.pica (DE-627)ELV047229942 (ELSEVIER)S1040-8428(19)30060-5 DE-627 ger DE-627 rakwb eng 610 VZ 610 VZ 44.52 bkl Fiorentino, Alba verfasserin aut Positron emission tomography with computed tomography imaging (PET/CT) for the radiotherapy planning definition of the biological target volume: PART 2 2019transfer abstract 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • FDG-PET has an important and promising role for the definition of RT target volume, including Stereotactic body RT for pancreatic cancer. • Choline PET/CT could be useful for identifying high-risk RT volumes, including nodes, for prostate cancer; while PSMA PET/CT is still under evaluation for the RT target definition. • FDG-PET has an important and promising role for the definition of RT target volume, including Stereotactic body RT for pancreatic cancer. • FDG PET-CT is the most sensitive imaging modality for detecting nodes metastases in gynecological cancer and has been shown to impact external-beam radiotherapy planning by modifying the treatment field. • FDG-PET/CT can be used to evaluate features at presentation, therapy response and it could be useful for assessing the oncological outcomes of anal and rectal cancer • FDG-PET has an important and promising role for the definition of RT target volume, including Stereotactic body RT for pancreatic cancer. • Choline PET/CT could be useful for identifying high-risk RT volumes, including nodes, for prostate cancer; while PSMA PET/CT is still under evaluation for the RT target definition. • FDG-PET has an important and promising role for the definition of RT target volume, including Stereotactic body RT for pancreatic cancer. • FDG PET-CT is the most sensitive imaging modality for detecting nodes metastases in gynecological cancer and has been shown to impact external-beam radiotherapy planning by modifying the treatment field. • FDG-PET/CT can be used to evaluate features at presentation, therapy response and it could be useful for assessing the oncological outcomes of anal and rectal cancer Target volume Elsevier Imaging Elsevier PET/CT Elsevier Radiotherapy Elsevier Laudicella, Riccardo oth Ciurlia, Elisa oth Annunziata, Salvatore oth Lancellotta, Valentina oth Mapelli, Paola oth Tuscano, Carmelo oth Caobelli, Federico oth Evangelista, Laura oth Marino, Lorenza oth Quartuccio, Natale oth Fiore, Michele oth Borghetti, Paolo oth Chiaravalloti, Agostino oth Ricci, Maria oth Desideri, Isacco oth Alongi, Pierpaolo oth Enthalten in Elsevier Science Dettori, D. ELSEVIER miR-214 in stroma cells and tumor progression 2016 Amsterdam [u.a.] (DE-627)ELV019637179 volume:139 year:2019 pages:117-124 extent:8 https://doi.org/10.1016/j.critrevonc.2019.03.008 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_11 GBV_ILN_20 GBV_ILN_70 GBV_ILN_100 GBV_ILN_2006 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2016 GBV_ILN_2048 44.52 Therapie Medizin VZ AR 139 2019 117-124 8 |
| allfieldsGer |
10.1016/j.critrevonc.2019.03.008 doi GBV00000000000665.pica (DE-627)ELV047229942 (ELSEVIER)S1040-8428(19)30060-5 DE-627 ger DE-627 rakwb eng 610 VZ 610 VZ 44.52 bkl Fiorentino, Alba verfasserin aut Positron emission tomography with computed tomography imaging (PET/CT) for the radiotherapy planning definition of the biological target volume: PART 2 2019transfer abstract 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • FDG-PET has an important and promising role for the definition of RT target volume, including Stereotactic body RT for pancreatic cancer. • Choline PET/CT could be useful for identifying high-risk RT volumes, including nodes, for prostate cancer; while PSMA PET/CT is still under evaluation for the RT target definition. • FDG-PET has an important and promising role for the definition of RT target volume, including Stereotactic body RT for pancreatic cancer. • FDG PET-CT is the most sensitive imaging modality for detecting nodes metastases in gynecological cancer and has been shown to impact external-beam radiotherapy planning by modifying the treatment field. • FDG-PET/CT can be used to evaluate features at presentation, therapy response and it could be useful for assessing the oncological outcomes of anal and rectal cancer • FDG-PET has an important and promising role for the definition of RT target volume, including Stereotactic body RT for pancreatic cancer. • Choline PET/CT could be useful for identifying high-risk RT volumes, including nodes, for prostate cancer; while PSMA PET/CT is still under evaluation for the RT target definition. • FDG-PET has an important and promising role for the definition of RT target volume, including Stereotactic body RT for pancreatic cancer. • FDG PET-CT is the most sensitive imaging modality for detecting nodes metastases in gynecological cancer and has been shown to impact external-beam radiotherapy planning by modifying the treatment field. • FDG-PET/CT can be used to evaluate features at presentation, therapy response and it could be useful for assessing the oncological outcomes of anal and rectal cancer Target volume Elsevier Imaging Elsevier PET/CT Elsevier Radiotherapy Elsevier Laudicella, Riccardo oth Ciurlia, Elisa oth Annunziata, Salvatore oth Lancellotta, Valentina oth Mapelli, Paola oth Tuscano, Carmelo oth Caobelli, Federico oth Evangelista, Laura oth Marino, Lorenza oth Quartuccio, Natale oth Fiore, Michele oth Borghetti, Paolo oth Chiaravalloti, Agostino oth Ricci, Maria oth Desideri, Isacco oth Alongi, Pierpaolo oth Enthalten in Elsevier Science Dettori, D. ELSEVIER miR-214 in stroma cells and tumor progression 2016 Amsterdam [u.a.] (DE-627)ELV019637179 volume:139 year:2019 pages:117-124 extent:8 https://doi.org/10.1016/j.critrevonc.2019.03.008 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_11 GBV_ILN_20 GBV_ILN_70 GBV_ILN_100 GBV_ILN_2006 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2016 GBV_ILN_2048 44.52 Therapie Medizin VZ AR 139 2019 117-124 8 |
| allfieldsSound |
10.1016/j.critrevonc.2019.03.008 doi GBV00000000000665.pica (DE-627)ELV047229942 (ELSEVIER)S1040-8428(19)30060-5 DE-627 ger DE-627 rakwb eng 610 VZ 610 VZ 44.52 bkl Fiorentino, Alba verfasserin aut Positron emission tomography with computed tomography imaging (PET/CT) for the radiotherapy planning definition of the biological target volume: PART 2 2019transfer abstract 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • FDG-PET has an important and promising role for the definition of RT target volume, including Stereotactic body RT for pancreatic cancer. • Choline PET/CT could be useful for identifying high-risk RT volumes, including nodes, for prostate cancer; while PSMA PET/CT is still under evaluation for the RT target definition. • FDG-PET has an important and promising role for the definition of RT target volume, including Stereotactic body RT for pancreatic cancer. • FDG PET-CT is the most sensitive imaging modality for detecting nodes metastases in gynecological cancer and has been shown to impact external-beam radiotherapy planning by modifying the treatment field. • FDG-PET/CT can be used to evaluate features at presentation, therapy response and it could be useful for assessing the oncological outcomes of anal and rectal cancer • FDG-PET has an important and promising role for the definition of RT target volume, including Stereotactic body RT for pancreatic cancer. • Choline PET/CT could be useful for identifying high-risk RT volumes, including nodes, for prostate cancer; while PSMA PET/CT is still under evaluation for the RT target definition. • FDG-PET has an important and promising role for the definition of RT target volume, including Stereotactic body RT for pancreatic cancer. • FDG PET-CT is the most sensitive imaging modality for detecting nodes metastases in gynecological cancer and has been shown to impact external-beam radiotherapy planning by modifying the treatment field. • FDG-PET/CT can be used to evaluate features at presentation, therapy response and it could be useful for assessing the oncological outcomes of anal and rectal cancer Target volume Elsevier Imaging Elsevier PET/CT Elsevier Radiotherapy Elsevier Laudicella, Riccardo oth Ciurlia, Elisa oth Annunziata, Salvatore oth Lancellotta, Valentina oth Mapelli, Paola oth Tuscano, Carmelo oth Caobelli, Federico oth Evangelista, Laura oth Marino, Lorenza oth Quartuccio, Natale oth Fiore, Michele oth Borghetti, Paolo oth Chiaravalloti, Agostino oth Ricci, Maria oth Desideri, Isacco oth Alongi, Pierpaolo oth Enthalten in Elsevier Science Dettori, D. ELSEVIER miR-214 in stroma cells and tumor progression 2016 Amsterdam [u.a.] (DE-627)ELV019637179 volume:139 year:2019 pages:117-124 extent:8 https://doi.org/10.1016/j.critrevonc.2019.03.008 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_11 GBV_ILN_20 GBV_ILN_70 GBV_ILN_100 GBV_ILN_2006 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2016 GBV_ILN_2048 44.52 Therapie Medizin VZ AR 139 2019 117-124 8 |
| language |
English |
| source |
Enthalten in miR-214 in stroma cells and tumor progression Amsterdam [u.a.] volume:139 year:2019 pages:117-124 extent:8 |
| sourceStr |
Enthalten in miR-214 in stroma cells and tumor progression Amsterdam [u.a.] volume:139 year:2019 pages:117-124 extent:8 |
| format_phy_str_mv |
Article |
| bklname |
Therapie |
| institution |
findex.gbv.de |
| topic_facet |
Target volume Imaging PET/CT Radiotherapy |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
miR-214 in stroma cells and tumor progression |
| authorswithroles_txt_mv |
Fiorentino, Alba @@aut@@ Laudicella, Riccardo @@oth@@ Ciurlia, Elisa @@oth@@ Annunziata, Salvatore @@oth@@ Lancellotta, Valentina @@oth@@ Mapelli, Paola @@oth@@ Tuscano, Carmelo @@oth@@ Caobelli, Federico @@oth@@ Evangelista, Laura @@oth@@ Marino, Lorenza @@oth@@ Quartuccio, Natale @@oth@@ Fiore, Michele @@oth@@ Borghetti, Paolo @@oth@@ Chiaravalloti, Agostino @@oth@@ Ricci, Maria @@oth@@ Desideri, Isacco @@oth@@ Alongi, Pierpaolo @@oth@@ |
| publishDateDaySort_date |
2019-01-01T00:00:00Z |
| hierarchy_top_id |
ELV019637179 |
| dewey-sort |
3610 |
| id |
ELV047229942 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV047229942</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230626015226.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">191021s2019 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.critrevonc.2019.03.008</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBV00000000000665.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV047229942</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1040-8428(19)30060-5</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.52</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Fiorentino, Alba</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Positron emission tomography with computed tomography imaging (PET/CT) for the radiotherapy planning definition of the biological target volume: PART 2</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2019transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">8</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• FDG-PET has an important and promising role for the definition of RT target volume, including Stereotactic body RT for pancreatic cancer. • Choline PET/CT could be useful for identifying high-risk RT volumes, including nodes, for prostate cancer; while PSMA PET/CT is still under evaluation for the RT target definition. • FDG-PET has an important and promising role for the definition of RT target volume, including Stereotactic body RT for pancreatic cancer. • FDG PET-CT is the most sensitive imaging modality for detecting nodes metastases in gynecological cancer and has been shown to impact external-beam radiotherapy planning by modifying the treatment field. • FDG-PET/CT can be used to evaluate features at presentation, therapy response and it could be useful for assessing the oncological outcomes of anal and rectal cancer</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• FDG-PET has an important and promising role for the definition of RT target volume, including Stereotactic body RT for pancreatic cancer. • Choline PET/CT could be useful for identifying high-risk RT volumes, including nodes, for prostate cancer; while PSMA PET/CT is still under evaluation for the RT target definition. • FDG-PET has an important and promising role for the definition of RT target volume, including Stereotactic body RT for pancreatic cancer. • FDG PET-CT is the most sensitive imaging modality for detecting nodes metastases in gynecological cancer and has been shown to impact external-beam radiotherapy planning by modifying the treatment field. • FDG-PET/CT can be used to evaluate features at presentation, therapy response and it could be useful for assessing the oncological outcomes of anal and rectal cancer</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Target volume</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Imaging</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">PET/CT</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Radiotherapy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Laudicella, Riccardo</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ciurlia, Elisa</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Annunziata, Salvatore</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lancellotta, Valentina</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mapelli, Paola</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tuscano, Carmelo</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Caobelli, Federico</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Evangelista, Laura</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Marino, Lorenza</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Quartuccio, Natale</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fiore, Michele</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Borghetti, Paolo</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Chiaravalloti, Agostino</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ricci, Maria</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Desideri, Isacco</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Alongi, Pierpaolo</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Dettori, D. ELSEVIER</subfield><subfield code="t">miR-214 in stroma cells and tumor progression</subfield><subfield code="d">2016</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV019637179</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:139</subfield><subfield code="g">year:2019</subfield><subfield code="g">pages:117-124</subfield><subfield code="g">extent:8</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.critrevonc.2019.03.008</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2006</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2016</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2048</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.52</subfield><subfield code="j">Therapie</subfield><subfield code="x">Medizin</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">139</subfield><subfield code="j">2019</subfield><subfield code="h">117-124</subfield><subfield code="g">8</subfield></datafield></record></collection>
|
| author |
Fiorentino, Alba |
| spellingShingle |
Fiorentino, Alba ddc 610 bkl 44.52 Elsevier Target volume Elsevier Imaging Elsevier PET/CT Elsevier Radiotherapy Positron emission tomography with computed tomography imaging (PET/CT) for the radiotherapy planning definition of the biological target volume: PART 2 |
| authorStr |
Fiorentino, Alba |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV019637179 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 VZ 44.52 bkl Positron emission tomography with computed tomography imaging (PET/CT) for the radiotherapy planning definition of the biological target volume: PART 2 Target volume Elsevier Imaging Elsevier PET/CT Elsevier Radiotherapy Elsevier |
| topic |
ddc 610 bkl 44.52 Elsevier Target volume Elsevier Imaging Elsevier PET/CT Elsevier Radiotherapy |
| topic_unstemmed |
ddc 610 bkl 44.52 Elsevier Target volume Elsevier Imaging Elsevier PET/CT Elsevier Radiotherapy |
| topic_browse |
ddc 610 bkl 44.52 Elsevier Target volume Elsevier Imaging Elsevier PET/CT Elsevier Radiotherapy |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
r l rl e c ec s a sa v l vl p m pm c t ct f c fc l e le l m lm n q nq m f mf p b pb a c ac m r mr i d id p a pa |
| hierarchy_parent_title |
miR-214 in stroma cells and tumor progression |
| hierarchy_parent_id |
ELV019637179 |
| dewey-tens |
610 - Medicine & health |
| hierarchy_top_title |
miR-214 in stroma cells and tumor progression |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV019637179 |
| title |
Positron emission tomography with computed tomography imaging (PET/CT) for the radiotherapy planning definition of the biological target volume: PART 2 |
| ctrlnum |
(DE-627)ELV047229942 (ELSEVIER)S1040-8428(19)30060-5 |
| title_full |
Positron emission tomography with computed tomography imaging (PET/CT) for the radiotherapy planning definition of the biological target volume: PART 2 |
| author_sort |
Fiorentino, Alba |
| journal |
miR-214 in stroma cells and tumor progression |
| journalStr |
miR-214 in stroma cells and tumor progression |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
2019 |
| contenttype_str_mv |
zzz |
| container_start_page |
117 |
| author_browse |
Fiorentino, Alba |
| container_volume |
139 |
| physical |
8 |
| class |
610 VZ 44.52 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Fiorentino, Alba |
| doi_str_mv |
10.1016/j.critrevonc.2019.03.008 |
| dewey-full |
610 |
| title_sort |
positron emission tomography with computed tomography imaging (pet/ct) for the radiotherapy planning definition of the biological target volume: part 2 |
| title_auth |
Positron emission tomography with computed tomography imaging (PET/CT) for the radiotherapy planning definition of the biological target volume: PART 2 |
| abstract |
• FDG-PET has an important and promising role for the definition of RT target volume, including Stereotactic body RT for pancreatic cancer. • Choline PET/CT could be useful for identifying high-risk RT volumes, including nodes, for prostate cancer; while PSMA PET/CT is still under evaluation for the RT target definition. • FDG-PET has an important and promising role for the definition of RT target volume, including Stereotactic body RT for pancreatic cancer. • FDG PET-CT is the most sensitive imaging modality for detecting nodes metastases in gynecological cancer and has been shown to impact external-beam radiotherapy planning by modifying the treatment field. • FDG-PET/CT can be used to evaluate features at presentation, therapy response and it could be useful for assessing the oncological outcomes of anal and rectal cancer |
| abstractGer |
• FDG-PET has an important and promising role for the definition of RT target volume, including Stereotactic body RT for pancreatic cancer. • Choline PET/CT could be useful for identifying high-risk RT volumes, including nodes, for prostate cancer; while PSMA PET/CT is still under evaluation for the RT target definition. • FDG-PET has an important and promising role for the definition of RT target volume, including Stereotactic body RT for pancreatic cancer. • FDG PET-CT is the most sensitive imaging modality for detecting nodes metastases in gynecological cancer and has been shown to impact external-beam radiotherapy planning by modifying the treatment field. • FDG-PET/CT can be used to evaluate features at presentation, therapy response and it could be useful for assessing the oncological outcomes of anal and rectal cancer |
| abstract_unstemmed |
• FDG-PET has an important and promising role for the definition of RT target volume, including Stereotactic body RT for pancreatic cancer. • Choline PET/CT could be useful for identifying high-risk RT volumes, including nodes, for prostate cancer; while PSMA PET/CT is still under evaluation for the RT target definition. • FDG-PET has an important and promising role for the definition of RT target volume, including Stereotactic body RT for pancreatic cancer. • FDG PET-CT is the most sensitive imaging modality for detecting nodes metastases in gynecological cancer and has been shown to impact external-beam radiotherapy planning by modifying the treatment field. • FDG-PET/CT can be used to evaluate features at presentation, therapy response and it could be useful for assessing the oncological outcomes of anal and rectal cancer |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_11 GBV_ILN_20 GBV_ILN_70 GBV_ILN_100 GBV_ILN_2006 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2016 GBV_ILN_2048 |
| title_short |
Positron emission tomography with computed tomography imaging (PET/CT) for the radiotherapy planning definition of the biological target volume: PART 2 |
| url |
https://doi.org/10.1016/j.critrevonc.2019.03.008 |
| remote_bool |
true |
| author2 |
Laudicella, Riccardo Ciurlia, Elisa Annunziata, Salvatore Lancellotta, Valentina Mapelli, Paola Tuscano, Carmelo Caobelli, Federico Evangelista, Laura Marino, Lorenza Quartuccio, Natale Fiore, Michele Borghetti, Paolo Chiaravalloti, Agostino Ricci, Maria Desideri, Isacco Alongi, Pierpaolo |
| author2Str |
Laudicella, Riccardo Ciurlia, Elisa Annunziata, Salvatore Lancellotta, Valentina Mapelli, Paola Tuscano, Carmelo Caobelli, Federico Evangelista, Laura Marino, Lorenza Quartuccio, Natale Fiore, Michele Borghetti, Paolo Chiaravalloti, Agostino Ricci, Maria Desideri, Isacco Alongi, Pierpaolo |
| ppnlink |
ELV019637179 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth |
| doi_str |
10.1016/j.critrevonc.2019.03.008 |
| up_date |
2024-07-06T22:19:28.825Z |
| _version_ |
1803869873846091776 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV047229942</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230626015226.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">191021s2019 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.critrevonc.2019.03.008</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBV00000000000665.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV047229942</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1040-8428(19)30060-5</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.52</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Fiorentino, Alba</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Positron emission tomography with computed tomography imaging (PET/CT) for the radiotherapy planning definition of the biological target volume: PART 2</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2019transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">8</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• FDG-PET has an important and promising role for the definition of RT target volume, including Stereotactic body RT for pancreatic cancer. • Choline PET/CT could be useful for identifying high-risk RT volumes, including nodes, for prostate cancer; while PSMA PET/CT is still under evaluation for the RT target definition. • FDG-PET has an important and promising role for the definition of RT target volume, including Stereotactic body RT for pancreatic cancer. • FDG PET-CT is the most sensitive imaging modality for detecting nodes metastases in gynecological cancer and has been shown to impact external-beam radiotherapy planning by modifying the treatment field. • FDG-PET/CT can be used to evaluate features at presentation, therapy response and it could be useful for assessing the oncological outcomes of anal and rectal cancer</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• FDG-PET has an important and promising role for the definition of RT target volume, including Stereotactic body RT for pancreatic cancer. • Choline PET/CT could be useful for identifying high-risk RT volumes, including nodes, for prostate cancer; while PSMA PET/CT is still under evaluation for the RT target definition. • FDG-PET has an important and promising role for the definition of RT target volume, including Stereotactic body RT for pancreatic cancer. • FDG PET-CT is the most sensitive imaging modality for detecting nodes metastases in gynecological cancer and has been shown to impact external-beam radiotherapy planning by modifying the treatment field. • FDG-PET/CT can be used to evaluate features at presentation, therapy response and it could be useful for assessing the oncological outcomes of anal and rectal cancer</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Target volume</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Imaging</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">PET/CT</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Radiotherapy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Laudicella, Riccardo</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ciurlia, Elisa</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Annunziata, Salvatore</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lancellotta, Valentina</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mapelli, Paola</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tuscano, Carmelo</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Caobelli, Federico</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Evangelista, Laura</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Marino, Lorenza</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Quartuccio, Natale</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fiore, Michele</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Borghetti, Paolo</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Chiaravalloti, Agostino</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ricci, Maria</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Desideri, Isacco</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Alongi, Pierpaolo</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Dettori, D. ELSEVIER</subfield><subfield code="t">miR-214 in stroma cells and tumor progression</subfield><subfield code="d">2016</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV019637179</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:139</subfield><subfield code="g">year:2019</subfield><subfield code="g">pages:117-124</subfield><subfield code="g">extent:8</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.critrevonc.2019.03.008</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2006</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2016</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2048</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.52</subfield><subfield code="j">Therapie</subfield><subfield code="x">Medizin</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">139</subfield><subfield code="j">2019</subfield><subfield code="h">117-124</subfield><subfield code="g">8</subfield></datafield></record></collection>
|
| score |
7.403078 |